Study of Ingaron's Effect on Efficacy and Resistance to Antibiotics in Community-acquired Pneumonia
Status:
Completed
Trial end date:
2019-05-30
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to effect of Ingaron®, a lyophilisate for the
preparation of a solution for intramuscular and subcutaneous administration of 100,000 IU
(LLC NPP Farmaklon, Russia) on the effectiveness of antibiotic therapy in patients with
community-acquired pneumonia who fell ill during the epidemiological rise of ARVI.